Valneva SE (VALN) stock
VALNNasdaqBiological Products, (No Diagnostic Substances)Fiscal year ends December 31
$5.16−0.21 (-3.82%)
Close on Nov 20, 2026Market cap $447.73MP/E –Yield –
Valneva gross profit
Gross profit is revenue minus the direct cost of the goods and services sold.
Valneva's gross profit for the twelve months ending Jun 30, 2026 was €23.44M, down 75.6% year over year. For fiscal 2025 it was €67.52M, down 5.0% from the year before. The highest annual figure on record is €160.17M in fiscal 2021.
Annual gross profit
| Period | Period end | Value | Change |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | €67.52M | -5.0% |
| FY2024 | Dec 31, 2024 | €71.04M | +34.5% |
| FY2023 | Dec 31, 2023 | €52.84M | +43.3% |
| FY2022 | Dec 31, 2022 | €36.86M | -77.0% |
| FY2021 | Dec 31, 2021 | €160.17M | +185.9% |
| FY2020 | Dec 31, 2020 | €56.02M | -23.7% |
| FY2019 | Dec 31, 2019 | €73.42M | – |
Quarterly gross profit
Change is against the same quarter a year earlier.
| Period | Period end | Value | Change |
|---|---|---|---|
| Q2 FY2026 | Jun 30, 2026 | €1.60M | -93.4% |
| Q1 FY2026 | Mar 31, 2026 | €4.72M | -82.0% |
| Q4 FY2025 | Dec 31, 2025 | €11.62M | -54.8% |
| Q3 FY2025 | Sep 30, 2025 | €5.50M | -72.7% |
| Q2 FY2025 | Jun 30, 2025 | €24.21M | +65.9% |
| Q1 FY2025 | Mar 31, 2025 | €26.19M | +147.2% |
| Q4 FY2024 | Dec 31, 2024 | €25.71M | +62.4% |
| Q3 FY2024 | Sep 30, 2024 | €20.15M | +17.8% |
| Q2 FY2024 | Jun 30, 2024 | €14.59M | +112.2% |
| Q1 FY2024 | Mar 31, 2024 | €10.59M | -18.7% |
| Q4 FY2023 | Dec 31, 2023 | €15.83M | – |
| Q3 FY2023 | Sep 30, 2023 | €17.10M | -86.4% |
| Q2 FY2023 | Jun 30, 2023 | €6.88M | – |
| Q1 FY2023 | Mar 31, 2023 | €13.03M | +63.1% |
| Q4 FY2022 | Dec 31, 2022 | -€10.31M | -104.1% |
| Q3 FY2022 | Sep 30, 2022 | €125.43M | – |
| Q2 FY2022 | Jun 30, 2022 | -€86.24M | -2173.6% |
| Q1 FY2022 | Mar 31, 2022 | €7.99M | -6.7% |
| Q4 FY2021 | Dec 31, 2021 | €249.91M | – |
| Q3 FY2021 | Sep 30, 2021 | -€102.46M | – |
| Q2 FY2021 | Jun 30, 2021 | €4.16M | – |
| Q1 FY2021 | Mar 31, 2021 | €8.57M | – |
See a number that looks wrong?